Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Next Previous
Trial Profile

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Cyclophosphamide (Primary) ; TRX 518 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Leap Therapeutics

    • Most Recent Events

    • 23 Oct 2020 Status changed from active, no longer recruiting to discontinued due to product development discontinued unrelated to safety.
    • 14 Nov 2019 According to a Leap Therapeutics media release, the company has completed enrollment in dose escalation phase of the trial and instead of additional enrollment through the expansion cohorts, the company has decided to reprioritize resources on the further development of the DKN-01 program. There were no safety or efficacy concerns leading to this decision, and patients who are benefitting from the combination therapy will continue to be treated in the study.
    • 13 Nov 2019 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top